Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference

Replimune Group, a clinical-stage biotechnology company based in Woburn, MA, announced a fireside chat presentation at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 1:00 PM ET.

Rhea-AI Summary

Replimune Group, a clinical-stage biotechnology company based in Woburn, MA, announced a fireside chat presentation at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 1:00 PM ET. The company focuses on developing tumor-directed oncolytic immunotherapies utilizing its proprietary RPx platform, which employs a potent HSV-1 backbone. This platform aims to induce systemic anti-tumor responses by killing tumors and altering the tumor microenvironment. Replimune was founded in 2015 and is publicly traded on NASDAQ under the symbol REPL.

Argus Session date unavailable

-1.36% session move Open Argus

Details

News Market Reaction – REPL

The recorded move for REPL in the trading session of this news was -1.36%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WOBURN, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY on Thursday, December 1, 2022 at 1:00 PM ET.

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the purpose of Replimune's presentation at the Piper Sandler Healthcare Conference?

Replimune's management team will discuss their innovative tumor-directed oncolytic immunotherapies and the RPx platform at the conference.

When is Replimune's presentation scheduled?

Replimune's presentation is set for December 1, 2022, at 1:00 PM ET.

What does the RPx platform developed by Replimune aim to achieve?

The RPx platform aims to maximize immunogenic cell death and stimulate a systemic anti-tumor immune response.

Where is the Piper Sandler Healthcare Conference being held?

The conference is taking place at the Lotte New York Palace in New York, NY.

What is the significance of the fireside chat for Replimune?

The fireside chat provides an opportunity for Replimune to share insights and developments related to their cancer treatment therapies.